Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response.

ABSTRACT:

Purpose

Therapy targeting CTLA-4 immune checkpoint provides increased survival in patients with advanced melanoma. However, immunotherapy is frequently associated with delayed and heterogeneous clinical responses and it is important to identify prognostic immunological correlates of clinical endpoints.

Experimental design

77 patients with stage III/IV melanoma were treated with ipilimumab alone every 3 weeks, during 9 weeks. Blood samples were collected at the baseline and before each dose for in depth immune monitoring.

Results

The median follow-up was 28 mo with a median survival of 7 mo. Survival and clinical benefit were significantly improved when absolute lymphocyte count at the baseline was above 1 × 10(9)/L. Notably, ipilimumab had a global effect on memory T

SUBMITTER: Felix J 

PROVIDER: S-EPMC5006913 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature